Therapeutic Hotline: Cysteinyl leukotriene receptor antagonist montelukast in the treatment of atopic dermatitis

Dermatologic Therapy

Volumn 23, Issue 1, 2010, Pages 90-93

  Broshtilova, Valentina ^a   Gantcheva, Mary ^b  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b Institute of Experimental Morphology and Anthropology Bulgarian Academy of Sciences   (Bulgaria)

Author keywords

Atopic dermatitis; Corticoid sparing agent; Montelukast

Indexed keywords

EMOLLIENT AGENT; METHYLPREDNISOLONE; MONTELUKAST;

ADULT; ARTICLE; ATOPIC DERMATITIS; CASE REPORT; DISEASE EXACERBATION; DISEASE SEVERITY; ERYTHEMA; EVENING DOSAGE; EXFOLIATIVE DERMATITIS; FEMALE; HUMAN; MALE; REMISSION; TREATMENT DURATION; TREATMENT OUTCOME;

ACETATES; ADULT; ASTHMA; DERMATITIS, ATOPIC; EOSINOPHILIA; EXUDATES AND TRANSUDATES; FEMALE; HUMANS; IMMUNOGLOBULIN E; LEUKOTRIENE ANTAGONISTS; MALE; METHYLPREDNISOLONE; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, LEUKOTRIENE; RHINITIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 76149089195     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2009.01295.x     Document Type: Article

References (15)

1. Yanase MD, Kateleen DB. The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis. J Am Acad Dermatol 2001 : 44 : 89 92.
2. Busse W. Leukotrienes and inflammation. Am J Respir Crit Care Med 1998 : 157 : 210 213.
3. Shauer U, Trube M, Jager R, et al. Blood eosinophils, eosinophil-derived proteins, and leukotriene C4 generation in the relation to bronchial hyperreactivity in children with atopic dermatitis. Allergy 1995 : 50 : 126 132.
4. Schichijo M, Ebisawa M, Miura K, et al. Relationship between histamine release and leukotirenes derived from atopic dermatitis donors. Int Arch Allergy Immunol 1995 : 107 : 587 591.
5. Shimizu T, Kristjansson S, Wennergren G, et al. Leukotriene B4 and C4 generation by blood leukocytes after ex vivo stimulation by Ca-ionophore and opsonized zymosan in children with atopic dermatitis. Pediatr Allergy Immunol 1994 : 5 : 95 98.
6. Donnelli A, Glass M, Minkwitz M, Casale T. The leukotriene D4 receptor antagonist ICI 204, 219 relieves the symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med 1995 : 151 : 1734 1739.
7. Capella GL, Grigerio E, Altomare G. A randomized trial of leukotriene receptor antagonist montelukast in moderete-to-severe atopic dermatitis of adults. Eur J Dermatol 2001 : 11 : 209 213.
8. Rahman MI, Choudhury AM, Islam MM. Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Med J 2006 : 15 : 85 88.
9. Veien NK, Busch-Sorensen M, Stausbol-Gron B. Montelukast treatment of moderate-to-severe atopic dermatitis in adults: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2005 : 53 : 147 149.
10. Angelova-Fischer I, Tsankov N. Successful treatment of severe atopic dermatitis with cysteinyl leukotriene receptor antagonist montelukast. Acta Dermatovenerol Alp Panonica Adriat 2005 : 14 : 115 119.
11. Pei AYS, Chan HHL, Leung TF. Montelukast in the treatment of children with moderate-to-severe atopic dermatitis: a pilot-study. Pediatr Allergy Immunol 2001 : 12 : 154 158.
12. Concha del Rio LE, Arroyave CM. A leukotriene antagonist (montelukast) in the treatment of atopic dermatitis in pediatric patients. Rev Alerg Mex 2003 : 50 : 187 191.
13. Price D, Rouleau M, Fletcher C, et al. Use of montelukast in tapering inhaled corticosteroid therapy: an open-label, 48-week trial. Curr Therapeut Res 2001 : 62 : 743 747.
14. Broshtilova V, Bardarov E, Antonov D, et al. Severe erythrodermic atopic dermatitis treated with montelukast. Skinmed 2003 : 2 : 134 136.
15. Hon KL, Leung TF, Ma KC, Wong Y, Fok TF. Brief case series: montelukast, at doses recommended for asthma treatment, reduces disease severity and increases soluble CD14 in children with atopic dermatitis. J Dermatol Treat 2005 : 16 : 15 18.